ITCC-089 Ramucirumab
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Promotor Name : Eli Lilly and Company
Investigator Name :
Trial registered on clinicaltrial.gov : NCT04145349
